BioVenture Consultants

BioWorld Articles by Cynthia Robbins-Roth, Ph.D.:

BioWorld Today

These columns originally appeared in BioWorld Today. They are reprinted here with the permission of Thomson BioWorld. If you have comments or relevant experiences you would like to share, or if you want to argue the points raised, please write to info@bioventureconsultants.com. Selected letters will be posted on the BioWorld site. Note that comments are subject to editing for clarity and length. Comments also can be sent directly to Dr. Robbins-Roth at info@bioventureconsultants.com.

As The BioWorld Turns, Part II:
Slimming Down With Brownies?
-- April 9, 2007

As Biotech Turns:
Fumbling, Bumbling And Posh Spice
-- March 26, 2007

Location, Location, Location:
Ceregene Bets on Better Delivery
-- March 12, 2007

Getting Closer to Nature:
The BrainCells Way
-- February 26, 2007

Is FIPCO Only Way To Go? Try Thinking 'Small Ball' -- February 12, 2007

Research at Gladstone Institute Translating Into New Products -- January 16, 2007

Unintended Consequences:
Mother Nature vs. Innovation
-- January 2, 2007

Weak Dollar Good For Biotech:
Outsourcing Trend May Reverse
-- December 18, 2006

Will 2007 Have Tidings Of Joy?
Some Thoughts On Next Year
-- December 4, 2006

Filling The Pipeline:
'Early Stage' Firm Varies In Eyes Of Beholder
-- November 20, 2006

Smell Of Dollars Burning On Breeze Of Pre-Election
-- November 6, 2006

Considering Brain Disease,
It's Time For New March Of Dimes
-- October 23, 2006

For Biotech CEOs,
Does VC Grass Seem Greener?
-- October 10, 2006

Fall Fun With Finances:
School's Back In Session
-- September 25, 2006

Still Turning: Racial Profiling,
Harassment, VC Execs Get Hip
-- August 1, 2006

As The BioWorld Turns:
From White Biotech To Stem Cell Fun
-- July 31, 2006

When Frank Talks,
Everyone Listens But Will They Act?
-- July 5, 2006

Mining Minds Of Doctors
For Better Predicting Drug Market
-- June 19, 2006

Biotechnology Soap Opera:
FDA, Sex, Politics, Religion
-- June 5, 2006

High-Priced Drugs Causing Angst;
Genzyme Stands Pat
-- May 22, 2006

How Frustrated Firm ReqMed
Created New Biotech Strategy
-- May 8, 2006

How Juvaris Found New Path,
Gathered Funds, Moved Ahead
-- April 24, 2006

Four Points Of Concern
As Biotechnology Grows
-- April 10, 2006

Need Public Market Access?
Go Knock On Heaven's Door (Corp.)
-- March 27, 2006

A Kinder, Gentler Place
For Biotech Hallmark: Start-ups
-- March 13, 2006

Love, Gambling And Biotech:
Side Effects Of CNS Drugs
-- February 27, 2006

Deal Terms Reward Products:
No Surprise From 2005 Trends
-- February 13, 2006

Much Like Peter Pan,
Big Pharma Won't Grow Up
-- January 30, 2006

Biotech's Redemption Chance:
Make Drugs, Foster Community
-- January 17, 2006

Biotech & Business Ethics:
Time To Face Up To Reality
-- December 12, 2005

For All Biotech's Forward
Progress, Issues Remain
-- November 4, 2005

Pricing, Data Leaks, Safety:
Biotech's Simmering Stew
-- November 3, 2005

Australian Biotechs Should
Rethink Financing Structure
-- September 28, 2005

The List: Innovative Models On
Which To Build Biotech
-- August 3, 2005

Building Biotechnology But
Not Via Biotech Companies
-- August 2, 2005

BIO's Past President Mulls
Biotech's Path Into Future
-- June 20, 2005

Broken? Readers Comment On Biotechnology Hurdles -- May 31, 2005

Biotech Model Broken;
Now What Can Be Done About It?
-- May 3, 2005

Lower IPO Valuations Quashing Early VC Biotechnology Funding -- May 2, 2005

A David vs. Goliath Biotech Story, With Goliath Winning -- April 8, 2005

Survival Of Fittest In 2005 For Biotechnology Firms -- March 14, 2005

Home Contact Us

Other Biotech Links:
Recap   BioWorld   Sedar   Wall Street Journal   Edgar  
BioMedNet  BioSpace  BIO